MX2012006265A - Formulaciones disacaridas hipersulfatadas. - Google Patents
Formulaciones disacaridas hipersulfatadas.Info
- Publication number
- MX2012006265A MX2012006265A MX2012006265A MX2012006265A MX2012006265A MX 2012006265 A MX2012006265 A MX 2012006265A MX 2012006265 A MX2012006265 A MX 2012006265A MX 2012006265 A MX2012006265 A MX 2012006265A MX 2012006265 A MX2012006265 A MX 2012006265A
- Authority
- MX
- Mexico
- Prior art keywords
- hypersulfated
- compounds
- agents
- disaccharides
- delivery
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
Abstract
Se describen los disacáridos hipersulfatado con utilidad en asma o padecimientos relacionados con as asma. Los compuestos se formulan con agentes que mejoran el suministro oral de los disacáridos hipersulfatados. Los agentes liberadores se seleccionan del grupo que consiste de polímeros naturales o sintéticos que tienen cadenas laterales iónicas como otros compuestos o tipos de compuestos que mejoran la disponibilidad de los disacáridos relacionados con el suministro del medicamento sin dichos agentes. Los disacáridos hipersulfatados se realizan de heparina o sales de los mismos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26636109P | 2009-12-03 | 2009-12-03 | |
PCT/US2010/057787 WO2011068721A1 (en) | 2009-12-03 | 2010-11-23 | Hypersulfated disaccharide formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2012006265A true MX2012006265A (es) | 2012-07-25 |
Family
ID=44082618
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012006265A MX2012006265A (es) | 2009-12-03 | 2010-11-23 | Formulaciones disacaridas hipersulfatadas. |
Country Status (10)
Country | Link |
---|---|
US (3) | US8546351B2 (es) |
EP (1) | EP2506711B1 (es) |
JP (2) | JP5860811B2 (es) |
KR (1) | KR101763440B1 (es) |
CN (1) | CN102711463B (es) |
CA (1) | CA2781923C (es) |
MX (1) | MX2012006265A (es) |
RU (1) | RU2576033C2 (es) |
TW (1) | TWI481408B (es) |
WO (1) | WO2011068721A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2012006265A (es) * | 2009-12-03 | 2012-07-25 | Opko Health Inc | Formulaciones disacaridas hipersulfatadas. |
US20130203695A1 (en) * | 2010-10-29 | 2013-08-08 | Opko Health, Inc. | Hypersulfated disaccharides to treat elastase related disorders |
JP5871500B2 (ja) * | 2011-06-20 | 2016-03-01 | 公益財団法人先端医療振興財団 | α−Klotho/FGF23複合体形成阻害化合物 |
JP6841609B2 (ja) | 2015-07-10 | 2021-03-10 | 3スキャン インコーポレイテッド | 組織学的染色の空間的多重化 |
US20190002596A1 (en) * | 2015-12-30 | 2019-01-03 | Shenzhen Hepalink Pharmaceutical Group Co., Ltd. | Sulfated heparin oligosaccharide and preparation method and application thereof |
WO2018035050A1 (en) | 2016-08-16 | 2018-02-22 | Opko Pharmaceuticals, Llc | Pure heptasulfated disaccharides having improved oral bioavailability |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3583799D1 (de) | 1985-01-11 | 1991-09-19 | Abbott Lab Ltd | Feste zubereitung mit langsamer freisetzung. |
ES2058129T3 (es) * | 1986-12-23 | 1994-11-01 | Fisons Plc | Composiciones farmaceuticas que comprenden una solucion acuosa de un derivado de piranoquinolina. |
GB8723896D0 (en) * | 1987-10-12 | 1987-11-18 | Aps Research Ltd | Controlled-release formulation |
US5990096A (en) | 1990-09-18 | 1999-11-23 | Hyal Pharmaceutical Corporation | Formulations containing hyaluronic acid |
US5498410A (en) | 1991-04-22 | 1996-03-12 | Gleich; Gerald J. | Method for the treatment of eosinophil-associated conditions with anionic polymers |
US5681555A (en) | 1991-04-22 | 1997-10-28 | Gleich; Gerald J. | Method for the treatment of bronchial asthma by parenteral administration of anionic polymers |
US6610329B2 (en) | 1993-04-22 | 2003-08-26 | Emisphere Technologies Inc. | Compositions for the delivery of antigens |
US5639469A (en) | 1994-06-15 | 1997-06-17 | Minnesota Mining And Manufacturing Company | Transmucosal delivery system |
US5690910A (en) * | 1995-08-18 | 1997-11-25 | Baker Norton Pharmaceuticals, Inc. | Method for treating asthma |
US5980865A (en) * | 1995-08-18 | 1999-11-09 | Baker Norton Pharmaceuticals, Inc. | Method for treating late phase allergic reactions and inflammatory diseases |
US6551616B1 (en) * | 1997-04-11 | 2003-04-22 | Abbott Laboratories | Extended release formulations of erythromycin derivatives |
US5827886A (en) * | 1997-05-07 | 1998-10-27 | Thione International, Inc. | Composition for relief of arthritis-induced symptoms |
US5968822A (en) * | 1997-09-02 | 1999-10-19 | Pecker; Iris | Polynucleotide encoding a polypeptide having heparanase activity and expression of same in transduced cells |
US6458383B2 (en) | 1999-08-17 | 2002-10-01 | Lipocine, Inc. | Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin |
WO2001032165A1 (en) * | 1999-10-29 | 2001-05-10 | Smithkline Beecham Corporation | Method for administering a phosphodiesterase 4 inhibitor |
US6635702B1 (en) | 2000-04-11 | 2003-10-21 | Noveon Ip Holdings Corp. | Stable aqueous surfactant compositions |
US7442388B2 (en) | 2000-05-10 | 2008-10-28 | Weers Jeffry G | Phospholipid-based powders for drug delivery |
MXPA03002934A (es) | 2000-10-10 | 2004-05-04 | Univ North Carolina | Composiciones y metodos para aumentar la permeabilidad paracelular a traves de las barreras epiteliales y endoteliales. |
US6824559B2 (en) | 2000-12-22 | 2004-11-30 | Advanced Cardiovascular Systems, Inc. | Ethylene-carboxyl copolymers as drug delivery matrices |
WO2002083700A2 (en) * | 2001-04-16 | 2002-10-24 | Ivax Research, Inc. | Hypersulfated disaccharides and methods of using the same for the treatment of inflammations |
US6663880B1 (en) | 2001-11-30 | 2003-12-16 | Advanced Cardiovascular Systems, Inc. | Permeabilizing reagents to increase drug delivery and a method of local delivery |
US20030180348A1 (en) | 2002-03-22 | 2003-09-25 | Levinson R. Saul | Transcellular drug delivery system |
US20040072796A1 (en) * | 2002-04-18 | 2004-04-15 | Embury Stephen H. | Method and composition for preventing pain in sickle cell patients |
US6855332B2 (en) | 2002-07-03 | 2005-02-15 | Lyfjathroun Hf. | Absorption promoting agent |
US7265097B2 (en) | 2002-08-20 | 2007-09-04 | Chitogenics, Inc. | Methods of drug delivery using sulphated chitinous polymers |
US7329638B2 (en) | 2003-04-30 | 2008-02-12 | The Regents Of The University Of Michigan | Drug delivery compositions |
US7943585B2 (en) * | 2003-12-22 | 2011-05-17 | Sandoz, Inc. | Extended release antibiotic composition |
WO2005075490A2 (en) * | 2004-02-03 | 2005-08-18 | Ivax Corporation | Synthesis of polysulfated uronic acid glycosides |
SI1778709T1 (sl) | 2004-08-05 | 2008-12-31 | Ivax Drug Res Inst Ltd | Polisulfatirani glikozidi in njihove soli |
WO2006017727A2 (en) | 2004-08-05 | 2006-02-16 | Ivax Corporation | Glycosides and salts thereof |
US20090215717A1 (en) | 2004-08-05 | 2009-08-27 | Ivax Drug Research Institute Ltd. | Sulfated oligosaccharides |
US7291598B2 (en) | 2005-01-04 | 2007-11-06 | Gp Medical, Inc. | Nanoparticles for protein drug delivery |
US20090082321A1 (en) | 2007-09-21 | 2009-03-26 | Allergan, Inc. | Steroid containing drug delivery systems |
AU2007267561B2 (en) | 2006-05-25 | 2012-05-17 | Momenta Pharmaceuticals, Inc. | Low molecular weight heparin composition and uses thereof |
MX2012006265A (es) * | 2009-12-03 | 2012-07-25 | Opko Health Inc | Formulaciones disacaridas hipersulfatadas. |
-
2010
- 2010-11-23 MX MX2012006265A patent/MX2012006265A/es active IP Right Grant
- 2010-11-23 CA CA2781923A patent/CA2781923C/en active Active
- 2010-11-23 EP EP10834963.0A patent/EP2506711B1/en active Active
- 2010-11-23 RU RU2012120833/15A patent/RU2576033C2/ru active
- 2010-11-23 JP JP2012542094A patent/JP5860811B2/ja active Active
- 2010-11-23 WO PCT/US2010/057787 patent/WO2011068721A1/en active Application Filing
- 2010-11-23 CN CN201080059542.6A patent/CN102711463B/zh active Active
- 2010-11-23 KR KR1020127016469A patent/KR101763440B1/ko active IP Right Grant
- 2010-11-24 US US12/953,831 patent/US8546351B2/en active Active
- 2010-12-03 TW TW099142239A patent/TWI481408B/zh active
-
2013
- 2013-08-28 US US14/011,807 patent/US9006211B2/en active Active
-
2015
- 2015-08-14 JP JP2015160206A patent/JP6158259B2/ja active Active
-
2016
- 2016-05-13 US US15/153,962 patent/US20160250242A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2781923C (en) | 2018-08-14 |
KR20120104583A (ko) | 2012-09-21 |
EP2506711A1 (en) | 2012-10-10 |
US8546351B2 (en) | 2013-10-01 |
TWI481408B (zh) | 2015-04-21 |
US20130345167A1 (en) | 2013-12-26 |
JP2013512904A (ja) | 2013-04-18 |
JP2016028039A (ja) | 2016-02-25 |
US20160250242A1 (en) | 2016-09-01 |
US20110136757A1 (en) | 2011-06-09 |
CN102711463A (zh) | 2012-10-03 |
CN102711463B (zh) | 2015-05-13 |
CA2781923A1 (en) | 2011-06-09 |
JP6158259B2 (ja) | 2017-07-05 |
JP5860811B2 (ja) | 2016-02-16 |
RU2576033C2 (ru) | 2016-02-27 |
KR101763440B1 (ko) | 2017-08-14 |
EP2506711B1 (en) | 2019-04-03 |
WO2011068721A1 (en) | 2011-06-09 |
RU2012120833A (ru) | 2014-01-10 |
EP2506711A4 (en) | 2013-04-10 |
TW201124142A (en) | 2011-07-16 |
US9006211B2 (en) | 2015-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JOP20180102B1 (ar) | مركب صيدلاني | |
IL219865A0 (en) | Acid salt forms of polymer-drug conjugates, compositions comprising the same, methods of producing the same and uses thereof | |
MX2013001677A (es) | Formulaciones estables de linaclotida. | |
UA109010C2 (en) | MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY | |
IN2012DN02736A (es) | ||
MX2013004491A (es) | Boronatos como inhibidores de arginasa. | |
EP2576578A4 (en) | POLYMORPHES OF 2'-O-FUCOSYLLACTOSE AND MANUFACTURE THEREOF | |
AU2012253759A8 (en) | Tricyclic sulfonamide compounds and methods of making and using same | |
MA33939B1 (fr) | 5-alcynyl-pyrimidines | |
UA109868C2 (ru) | Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar) | |
EP2707379A4 (en) | USE OF PURIFIED 2'-FUCOSYLLACTOSIS, 3-FUCOSYLLACTOSIS AND LACTODIFUCOTETRAOSE AS PREBIOTICS | |
MX2012007098A (es) | Derivados fenolicos y su uso farmaceutico o cosmetico. | |
UA111065C2 (uk) | Композиції норибогаїну | |
MY156938A (en) | Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application | |
AU2012258977A8 (en) | Inhibitors of LRRK2 kinase activity | |
MX2012007161A (es) | Derivados fenolicos y su uso farmaceutico o cosmetico. | |
MX2019012939A (es) | Formulaciones que contienen linaclotida para administracion oral. | |
IT1402907B1 (it) | Composizioni topiche per mantenere o ripristinare l'integrita' delle mucose. | |
UA111717C2 (uk) | Склад для перорального введення і ліпофільні солі метилналтрексону | |
MX2012006265A (es) | Formulaciones disacaridas hipersulfatadas. | |
MY173521A (en) | Trpv4 antagonists | |
WO2012048129A3 (en) | Inhibitors of polo-like kinase | |
MX2011013032A (es) | Inhibidores de fosfatidilinositol 3-cinasa. | |
PL2768936T3 (pl) | Preparaty, ich zastosowanie jako środków do zmywania naczyń lub do wytwarzania środków do zmywania naczyń i ich wytwarzanie | |
MX2013002948A (es) | Composiciones farmaceuticas y nutraceuticas de acido abscisico. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |